Piper Sandler initiates Abbott Laboratories with "overweight" rating, $131 PT
Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per share. Piper Sandler emphasizes Abbott’s attractive valuation, strong financial outlook,
Abbott Laboratories stock underperforms Wednesday when compared to competitors
The stock's fall snapped a two-day winning streak.
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those losses by quickly developing and marketing COVID-19 diagnostic tests.
How Does Abbott Laboratories (ABT) Stack Up Against Its Industry Peers?
Abbott Laboratories (ABT) stock saw a decline, ending the day at $114.88 which represents a decrease of $-3.25 or -2.75% from the prior close of $118.13. The stock opened at $117.5 and touched a low of $114.
Abbott Laboratories (ABT) Gets a Buy from Wells Fargo
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report),
Calculating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Key Insights The projected fair value for Abbott Laboratories is US$132 based on 2 Stage Free Cash Flow to Equity
Abbott Laboratories stock underperforms Friday when compared to competitors
Abbott Laboratories closed $5.24 short of its 52-week high ($121.64), which the company achieved on March 8th.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Fintel on MSN11h
Piper Sandler Initiates Coverage of Abbott Laboratories (ABT) with Overweight Recommendation
Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories (NYSE:ABT) with a ...
Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst
Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...
Buy Rating on Abbott Laboratories: Undervalued with Strong Growth Prospects Despite NEC Litigation
Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...
Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change
Cardiovascular disease is rising, and Abbott Laboratories is well-positioned in the CVD treatment space. Read why I'm neutral ...
drugdeliverybusiness1d
Class action suit targets Abbott FreeStyle Libre amid claims of data sharing
Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...